ELKHART, Ind., Sept. 10, 2026 /PRNewswire/ -- THOR Industries, Inc. (NYSE: THO), the world's largest manufacturer of recreational vehicles, today announced further leadership changes as a part of the previously announced evolution of its North American RV operating model to amplify the identified benefits of this evolution across our North American RV companies.

Effective immediately, Ken Walters, President of Jayco and leader of the Jayco and Tiffin Motorhomes group, will assume the role of President of North American RV operations. Walters will report to THOR executive management in Elkhart and will coordinate North American RV operations across all of THOR's operating companies as they implement and build upon the initiatives of THOR's North American RV Group operating model. Nic Martin, Vice President of Sales at Jayco, will become President of Jayco. Martin brings an extensive background to the role in the sales and operations of Jayco and is well positioned to keep Jayco on its successful path within the industry.

"Ken has done an outstanding job as President of Jayco, guiding a highly respected towable and motorized brand through a difficult market while putting dealers and retail customers first. Early successes of the Jayco and Tiffin Motorhomes group are promising, and we are eager to amplify those successes across all of our North American RV entities," said Bob Martin, President and CEO of THOR.

As THOR's leadership teams within the previously announced two RV groups evaluated their approach to achieving benefits of consolidation, it became clear that unified coordination of execution across North American RV would bring the enterprise more benefits on an accelerated timeline. For THOR going forward, there will be three distinct operating groups: North American RV, European, and Supply.

"We are proud of the work that our leadership teams have done as we work towards achieving the objectives of our evolved North American RV operating model and begin realizing its expected benefits," stated Bob Martin. "Our structure has been decentralized for decades, so this is an involved process but one with potentially significant benefits and cost savings as its outcome. As our leadership teams within the two RV groups worked through the evaluation phase of this process during the previous two quarters, it became clear to us that we could achieve a greater magnitude of benefits with additional coordination across all of our RV companies that will position THOR to deliver positive benefits for our dealer partners and retail customers, address affordability and enhance our margin profile."

To further advance this objective of amplifying benefits across our North American RV group, Mike Ritchie, Vice President of Finance at Jayco, will become CFO of North American RV operations. Ritchie will fill a pivotal role with a focus on financial performance and aligning synergistic initiatives across the THOR North American RV operations. Ritchie will continue to report to Colleen Zuhl, Senior Vice President and Chief Financial Officer of THOR. Walters and Ritchie will remain heavily involved with the operational and financial performance of the North American RV group at the local level, ensuring operational excellence and the successful implementation of key initiatives.

Trey Miller, Vice President of Marketing at Jayco, will be promoted to Chief Marketing Officer of the THOR North American RV operations. Prior to joining Jayco, Miller served in lead marketing positions with both Dometic and Stag Parkway. In his new role, Miller will be the manager of the marketing teams across the THOR North American RV operations.

Additionally, Troy James, currently the Chief Operating Officer of the Thor Motor Coach and Keystone group, will become President of Keystone. James brings an extensive operational background to the role, with both North American and European sales and operational experience. James will continue his focus of enhancing organizational performance and reestablishing Keystone's prominent position within the industry.

"We are extremely excited about the direction that our North American RV operating model has taken," said Todd Woelfer, Senior Vice President and Chief Operating Officer of THOR. "Our operating companies have taken this challenge head-on and identified a path towards enhanced synergies and structural improvements that further the alignment of our operating companies. We are focused on realizing the benefits of our evolved operating model, driving out costs within the Company to strengthen our earnings profile and continue leading the industry in addressing the affordability concerns of RV retail customers. We will not simply stand by and pass rising costs on to pressured retail customers and dealers while waiting for an inflection at the retail level. We believe it is essential to our long-term positioning to prioritize the health of the retail market rather than abdicate responsibility. The strength of our leadership teams and the initiatives we are implementing will make us a key component of the solutions to the challenges facing our industry."

About THOR Industries, Inc.

THOR Industries is the sole owner of operating companies which, combined, represent the world's largest manufacturer of recreational vehicles.

For more information on the Company and its products, please go to www.thorindustries.com.

Forward-Looking Statements

This release includes certain statements that are "forward-looking" statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are made based on management's current expectations and beliefs regarding future and anticipated developments and their effects upon THOR, and inherently involve uncertainties and risks. These forward-looking statements are not a guarantee of future performance. We cannot assure you that actual results will not differ materially from our expectations. Factors which could cause materially different results include, among others: the impact of inflation on the cost of our products as well as on general consumer demand; the effect of raw material and commodity price fluctuations, including the impact of tariffs, and/or raw material, commodity or chassis supply constraints; the impact of war, military conflict, terrorism and/or cyber-attacks, including state-sponsored or ransom attacks; the impact of sudden or significant adverse changes in the cost and/or availability of energy or fuel, including those caused by geopolitical events, on our costs of operation, on raw material prices, on our suppliers, on our independent dealers or on retail customers; the dependence on a small group of suppliers for certain components used in production, including chassis; interest rates and interest rate fluctuations and their potential impact on the general economy and, specifically, on our independent dealers and consumers and our profitability; the ability to ramp production up or down quickly in response to rapid changes in demand or market share while also managing associated costs, including labor-related costs and production capacity costs; the level and magnitude of warranty and recall claims incurred; the ability of our suppliers to financially support any defects in their products; the financial health of our independent dealers and their ability to successfully manage through various economic conditions; legislative, trade, regulatory and tax law and/or policy developments including their potential impact on our independent dealers, retail customers or on our suppliers; the costs of compliance with governmental regulation; the impact of an adverse outcome or conclusion related to current or future litigation or regulatory audits or investigations; public perception of and the costs related to environmental, social and governance matters; legal and compliance issues including those that may arise in conjunction with recently completed transactions; the ability to realize anticipated benefits of strategic realignments or other reorganizational actions; the level of consumer confidence and the level of discretionary consumer spending; the impact of exchange rate fluctuations; restrictive lending practices which could negatively impact our independent dealers and/or retail consumers; management changes; the success of new and existing products and services; the ability to maintain strong brands and develop innovative products that meet consumer demands; changes in consumer preferences; the risks associated with acquisitions, including: the pace and successful closing of an acquisition, the integration and financial impact thereof, the level of achievement of anticipated operating synergies from acquisitions, the potential for unknown or understated liabilities related to acquisitions, the potential loss of existing customers of acquisitions and our ability to retain key management personnel of acquired companies; a shortage of necessary personnel for production and increasing labor costs and related employee benefits to attract and retain production personnel in times of high demand; the loss or reduction of sales to key independent dealers, and stocking level decisions of our independent dealers; disruption of the delivery of units to independent dealers or the disruption of delivery of raw materials, including chassis, to our facilities; increasing costs for freight and transportation; the ability to protect our information technology systems, including confidential and personal information, from data breaches, cyber-attacks and/or network disruptions; asset impairment charges; competition; the impact of losses under repurchase agreements; the impact of the strength of the U.S. dollar on international demand for products priced in U.S.

Tom Fitzgerald, Chief Financial Officer, Announces his Retirement

John Tattory, to become Interim Chief Financial Officer

BOSTON, Sept. 10, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, today announced the retirement of its Chief Financial Officer, Tom Fitzgerald. Mr. Fitzgerald has served as the Chief Financial Officer of TransCode Therapeutics since July 2018, during which time he helped lead the company through its initial public offering, the launch of its clinical program for lead product candidate, TTX-MC138, and most recently its acquisition of Polynoma and license agreement with Oncolytics in order to broaden the company's pipeline of innovative oncology product candidates.

Philippe P. Calais, Ph.D, Chairman of the Board and CEO said: "On behalf of the Board, I wish to thank Tom for his many years of dedicated service to the company and its key stakeholders, starting all the way back when TransCode was a small, discovery stage company with limited resources but outsized ambitions. Since the earliest days of the company Tom has worked tirelessly to keep us funded and on track, all so that we might have the opportunity to bring life-changing therapeutics to those cancer patients who need it most. We wish Tom every happiness in his well-earned retirement."

Mr. Fitzgerald will resign as Chief Financial Officer and as a director of the company, effective immediately, after which he will continue to provide transition services to the company.

John Tattory, will serve as Interim Chief Financial Officer, effective immediately. John is a senior executive with over 25 years of financial and operational management and leadership, including directing U.S. and international financial operations, strategic transactions, licensing and collaboration arrangements, and equity and debt financings for private and publicly traded pharmaceutical, medical device, and biotechnology companies from development stage through commercialization. He started his career at Ernst &Young LLP, then became Finance Director at Bristol-Myers Squibb and Tyco International. He was Chief Financial Officer of Cerapedics, Inc. and Windtree Therapeutics, Inc. (Nasdaq: WINT). Currently, John is a Managing Director at Stout Risius Ross, LLC, a global advisory firm, where he provides Consulting CFO services primarily to privately held life science companies. His broad expertise includes raising capital and investor relations (buyside & sellside), financial planning and analysis, and public financial reporting and accounting.

About TransCode Therapeutics

TransCode Therapeutics is an immuno-oncology and targeted cancer therapy company with a focus on treating advanced malignancy. The Company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors that overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode has a portfolio of other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells.

Forward-Looking Statements

This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements concerning the above-described leadership transition and the potential of the company's product candidates. Any forward-looking statements in this press release are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the risks associated with drug discovery and development; the risk that the results of clinical trials will not be consistent with TransCode's preclinical studies or expectations or with results from previous clinical trials; risks associated with the conduct of clinical trials; risks associated with TransCode's financial condition and its need to obtain additional funding to support its business activities, including TransCode's ability to continue as a going concern; risks associated with the timing and outcome of TransCode's planned regulatory submissions; risks associated with obtaining, maintaining and protecting intellectual property; risks associated with TransCode's ability to enforce its patents against infringers and defend its patent portfolio against challenges from third parties; risks of competition from other companies developing products for similar uses; risks associated with TransCode's dependence on third parties; and risks associated with geopolitical events and pandemics. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause TransCode's actual results to differ from those contained in or implied by the forward-looking statements, see the section entitled "Risk Factors" in TransCode's Annual Report on Form 10-K for the year ended December 31, 2025, as well as discussions of potential risks, uncertainties and other important factors in any subsequent TransCode filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this release; TransCode undertakes no duty to update this information unless required by law.

SOURCE TransCode Therapeutics, Inc.

Share this article

TORONTO, Sept. 10, 2026 /PRNewswire/ -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, today announced that it has filed a preliminary short form base shelf prospectus (the "Shelf Prospectus") with the securities regulatory authorities in each of the provinces and territories of Canada, together with a corresponding registration statement on Form F-10 (the "Registration Statement") with the United States Securities and Exchange Commission (the "SEC") under the U.S./Canada Multijurisdictional Disclosure System.

No securities are being offered in connection with this announcement. The filing of the Shelf Prospectus does not obligate the Company to undertake an offering, and there can be no assurance that any securities will be offered or sold thereunder.

Once a receipt has been issued for the final short form base shelf prospectus and the Registration Statement has become effective, the filings will permit Cardiol to offer and sell, from time to time during the 25-month period the final short form base shelf prospectus remains effective, Class A common shares, debt securities, warrants, subscription receipts, units, or any combination of such securities, having an aggregate initial offering price of up to US$150 million, or the equivalent in other currencies.

Copies of the Shelf Prospectus are available under the Company's respective profiles on SEDAR+ at www.sedarplus.ca and EDGAR at www.sec.gov, and are available on the Company's website at www.cardiolrx.com.

"Cardiol is entering an exciting period, with several potentially transformative milestones ahead," said David Elsley, President and Chief Executive Officer of Cardiol Therapeutics. "Our pivotal Phase III MAVERIC trial is approaching target enrollment and is designed to generate clinical evidence to support a New Drug Application for CardiolRx™ in recurrent pericarditis, subject to favorable results and regulatory input. This represents an important step toward delivering a differentiated treatment for patients living with this debilitating disease. Positive Phase II ARCHER findings in acute myocarditis and the continued advancement of CRD-38 toward first-in-human clinical development reinforce our confidence in the breadth and promise of our pipeline."

Expanded Program and Expense Disclosure at the Request of Staff of the OSC

In connection with a review by staff of the Ontario Securities Commission (the "OSC"), and at the request of OSC staff, the Shelf Prospectus includes additional disclosure that supplements the Company's management's discussion and analysis for the year ended December 31, 2025, and for the three and six months ended June 30, 2026. No previously filed financial statement has been restated or amended, and there is no change to the Company's reported research and development or general and administrative expenses, net loss, cash flows, cash position, or financial position for any period. The additional disclosure provides additional information regarding:

- tabular and narrative disclosure setting out, for the Company's research and development programs, the original and updated target completion dates, the original estimated cost of the current stage of development, cumulative external program expenditures incurred to date, and estimated remaining costs to completion, together with explanatory notes describing program status, anticipated next steps, and the basis on which the estimates were prepared;

- the allocation of external research and development expenditures among those programs for each comparative period presented, together with narrative explaining the ordinary course development activities underlying period-over-period changes;

- the disaggregation of the components of the Company's general and administrative expenses, together with additional narrative outlining the specific factors and circumstances contributing to period-over-period changes in the material components; and

- the principal purposes for which the net proceeds of the Company's October 2024 financing completed under the Company's prior base shelf prospectus were intended to be used, and a comparison of the intended and actual use of those proceeds.

The Company will also incorporate prospective disclosure changes to its continuous disclosure filings relating to the foregoing information. The additional disclosure provides additional narrative and component-level detail regarding amounts and activities already reflected in the Company's previously filed financial statements and continuous disclosure record.

In addition, and at the request of OSC staff, the Company will be filing the following material contracts concurrently with the filing of the Shelf Prospectus:

- Exclusive Master Services Agreement dated April 17, 2018, between the Company and Dalton Chemical Laboratories, Inc., operating as Dalton Pharma Services; and

- Amendments dated December 7, 2018, July 2, 2019, September 11, 2019, October 28, 2019, and November 12, 2019, to the Exclusive Supply Agreement dated September 28, 2018, between the Company and Purisys, LLC, as successor and assign of Noramco, Inc.

- Development Agreement dated August 28, 2018, between the Company and the Instituto Tecnológico y de Estudios Superiores de Monterrey's Clinical Academic Research Organization, S.A. de C.V;

About Cardiol Therapeutics

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The Company's lead small-molecule drug candidate, CardiolRx™, modulates inflammasome pathway activation, an intracellular innate immune system response known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure.

The MAVERIC Program is evaluating CardiolRx™ for the treatment of recurrent pericarditis, an inflammatory disease of the pericardium associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, which can lead to physical limitations, reduced quality of life, emergency department visits, and hospitalizations. The program comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing pivotal Phase III MAVERIC trial (NCT06708299). The U.S. FDA has granted Orphan Drug Designation to CardiolRx™ for the treatment of pericarditis, including recurrent pericarditis.

The ARCHER Program also studied CardiolRx™, specifically in acute myocarditis—an important cause of acute and fulminant heart failure in young adults and a leading cause of sudden cardiac death in individuals under 35 years of age. The program comprises the completed Phase II ARCHER study (NCT05180240), which evaluated the safety, tolerability, and efficacy of CardiolRx™ in this patient population.

The Company is also developing CRD-38, a novel, subcutaneously administered drug formulation intended for the treatment of inflammatory heart disease, including heart failure—a leading cause of death and hospitalization in the developed world, with associated healthcare costs in the United States exceeding US$30 billion per year.

For more information about Cardiol Therapeutics, please visit cardiolrx.com.

Cautionary statement regarding forward-looking information:

This news release contains "forward-looking information" within the meaning of applicable securities laws. All statements, other than statements of historical fact, that address activities, events, or developments that Cardiol believes, expects, or anticipates will, may, could, or might occur in the future are "forward-looking information". Forward looking information contained herein may include, but is not limited to statements regarding the Company's focus on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease; the Company's intended clinical studies and trial activities and timelines associated with such activities, including the Company's plan to complete the Phase III study in recurrent pericarditis with CardiolRx™; the Company's plan to advance the development of CRD-38, a novel subcutaneous formulation intended for the treatment of inflammatory heart disease, including heart failure; the Company's future financing plans, including the potential filing of a prospectus supplement; and the Company's future approach to its continuous disclosure filings. Forward-looking information contained herein reflects the current expectations or beliefs of Cardiol based on information currently available to it and is based on certain assumptions and is also subject to a variety of known and unknown risks and uncertainties and other factors that could cause the actual events or results to differ materially from any future results, performance or achievements expressed or implied by the forward looking information, and are not (and should not be considered to be) guarantees of future performance. These risks and uncertainties and other factors include the risks and uncertainties referred to in the Company's Annual Information Form filed with the Canadian securities administrators and U.S. Securities and Exchange Commission on March 31, 2026, available on SEDAR+ at sedarplus.ca and EDGAR at sec.gov, as well as the risks and uncertainties associated with product commercialization and clinical studies. These assumptions, risks, uncertainties, and other factors should be considered carefully, and investors should not place undue reliance on the forward-looking information, and such information may not be appropriate for other purposes.

RACINE, Wis., Sept. 10, 2026 /PRNewswire/ -- Modine (NYSE: MOD), a diversified global leader in thermal management technology and solutions, today announced that it will become Modexus Solutions after completing the spinoff of its Performance Technologies business and merger with Gentherm. Under applicable law, the name change will be subject to approval by Modine's shareholders. Once effective, Modexus Solutions will trade on the New York Stock Exchange under Modine's current ticker symbol, "MOD."

The new name reflects the company's position as a diversified thermal management company serving high-growth markets, including data center cooling, commercial HVAC and refrigeration. The Modexus Solutions name was selected to carry forward Modine's century-long heritage while underscoring the company's leadership in innovative, connected thermal systems and solutions.

"Modexus Solutions captures who we are: a company that combines deep thermal management expertise with the innovation and agility required to help customers solve increasingly complex challenges," said Neil D. Brinker, Modine President and Chief Executive Officer. "Through our 80/20 framework, we will continue to evolve our portfolio of products toward fit-for-purpose systems that maximize performance and reduce resource usage."

The transaction, which was overwhelmingly approved by Gentherm shareholders at a special meeting held on September 10, 2026, is currently expected to close on October 1, 2026, subject to the satisfaction or waiver of customary closing conditions. Upon closing, Modexus Solutions will continue to be led by Neil D. Brinker and Michael (Mick) Lucareli as CEO and CFO, respectively, and the current Board of Directors.

"We congratulate the Gentherm team on reaching this milestone, and we thank our Performance Technologies employees for their continued dedication as we move toward closing," Brinker added. "We believe this transaction will create two stronger companies, each better positioned to serve its end markets, accelerate growth and drive long-term value for shareholders, customers and employees."

The Company expects to call a special meeting of stockholders to vote on the proposed name change within three months following the closing of the transaction. Details of the meeting will be announced at a later date.

About Modine

For more than 100 years, Modine has solved the toughest thermal management challenges for mission-critical applications. Our purpose of Engineering a Cleaner, Healthier World™ means we are always evolving our portfolio of technologies to provide the latest heating, cooling, and ventilation solutions. Through the hard work of more than 13,000 employees worldwide, our businesses advance our purpose with systems that improve air quality, reduce energy and water consumption, lower harmful emissions, enable cleaner running vehicles, and use environmentally friendly refrigerants. Modine is a global company headquartered in Racine, Wisconsin (U.S.), with operations in North America, South America, Europe, and Asia. For more information about Modine, visit modine.com.

No Offer or Solicitation 

This press release is not intended to and does not constitute an offer to sell or the solicitation of an offer to buy or exchange any securities or a solicitation of any vote or approval in any jurisdiction, including with respect to the proposed name change, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. It does not constitute a prospectus or prospectus equivalent document. No offering or sale of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended (the "Securities Act"), and otherwise in accordance with applicable law. This press release is not a substitute for the proxy statement or any other document that Modine may file with the SEC in connection with the proposed name change.

Additional Information and Where to Find It

In connection with the proposed transaction between Modine and Gentherm (the "Proposed Transaction"), the parties have filed relevant materials with the U.S. Securities and Exchange Commission (the "SEC"), including, among other filings, a registration statement on Form S-4 filed by Gentherm (the "Form S-4"), which was declared effective by the SEC and includes a definitive proxy statement/prospectus of Gentherm, which has been mailed to shareholders of Gentherm, and a registration statement on Form 10 (the "Form 10") filed by Platinum SpinCo Inc., a wholly owned subsidiary of Modine ("Spinco"), which was declared effective by the SEC, that incorporates by reference certain portions of the Form S-4 and serves as an information statement/prospectus in connection with the spin-off of SpinCo from Modine. INVESTORS AND SECURITY HOLDERS OF GENTHERM AND MODINE ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS, THE INFORMATION STATEMENT/PROSPECTUS AND ANY OTHER DOCUMENTS THAT HAVE BEEN OR MAY BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT GENTHERM, MODINE, SPINCO, THE PROPOSED TRANSACTION AND RELATED MATTERS. Investors and security holders may obtain free copies of the Form S-4 and the proxy statement/prospectus and other documents filed with the SEC by Gentherm, SpinCo or Modine through the website maintained by the SEC at www.sec.gov. Copies of the documents filed with the SEC by Gentherm are available free of charge on Gentherm's website at gentherm.com under the tab "Investors & Media" and under the heading "Financial Info" and subheading "SEC Filings." Copies of the documents filed with the SEC by Modine and SpinCo are available free of charge on Modine's website at modine.com under the tab "Investors" and under the heading "Financials" and subheading "SEC Filings."

In connection with the proposed change of Modine's corporate name, Modine intends to file a proxy statement with the SEC. This press release is not a substitute for the proxy statement or any other document that Modine may file with the SEC. INVESTORS AND SECURITY HOLDERS OF MODINE ARE URGED TO READ THE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS FILED OR TO BE FILED WITH THE SEC, AND ANY AMENDMENTS OR SUPPLEMENTS THERETO, CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Investors and security holders will be able to obtain free copies of the proxy statement and other documents filed by Modine with the SEC through the website maintained by the SEC at www.sec.gov and on Modine's website at modine.com under the tab "Investors" and under the heading "Financials" and subheading "SEC Filings."

Participants in the Solicitation

Modine and its directors and executive officers may be deemed to be participants in the solicitation of proxies from Modine's shareholders in respect of the proposed name change. Information regarding Modine's directors and executive officers, including a description of their direct and indirect interests, by security holdings or otherwise, is contained in Modine's proxy statement for its 2026 annual meeting of shareholders, filed with the SEC on July 10, 2026, and in Modine's Annual Report on Form 10-K for the fiscal year ended March 31, 2026, filed with the SEC on May 27, 2026. To the extent holdings of Modine securities by Modine's directors and executive officers have changed since the amounts set forth in those filings, such changes have been or will be reflected on Statements of Change in Ownership on Form 4 filed with the SEC. Additional information regarding the interests of participants in the solicitation of proxies in respect of the proposed name change will be included in the proxy statement relating to that matter when it is filed with the SEC. Free copies of these documents may be obtained as described in "Additional Information and Where to Find It" above.

Forward-Looking Statements

This press release includes "forward-looking statements" as that term is defined in Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the Proposed Transaction. These forward-looking statements may be identified by the words "believe," "feel," "project," "expect," "anticipate," "appear," "estimate," "forecast," "outlook," "target," "endeavor," "seek," "predict," "intend," "suggest," "strategy," "plan," "may," "could," "should," "will," "would," "will be," "will continue," "will likely result," or the negative thereof or variations thereon or similar terminology generally intended to identify forward-looking statements. All statements, other than historical facts, including, but not limited to, statements regarding the expected timing of the Proposed Transaction, the expected benefits of the Proposed Transaction and the timing of the special meeting of shareholders to vote on the proposed name change are forward-looking statements.

These forward-looking statements are based on Gentherm's and Modine's current expectations and are subject to risks and uncertainties surrounding future expectations generally. Actual results could differ materially from those currently anticipated due to a number of risks and uncertainties, many of which are beyond Gentherm's and Modine's control.

Beverly L. Propst to Retire in January

ST. LOUIS, Sept. 10, 2026 /PRNewswire/ -- Graybar, a leading distributor of electrical, industrial, automation and connectivity products and provider of related supply chain management and logistics services, today announced the retirement of Senior Vice President - Human Resources, Beverly L. Propst, effective January 1, 2027.

A licensed attorney, Propst joined Graybar in 2002 as a Corporate Counsel in Graybar's Legal Department. She was promoted to Senior Corporate Counsel in 2003 and was named Vice President - Human Resources in 2008. In 2009, Propst was elected to Graybar's Board of Directors and promoted to her current position of Senior Vice President - Human Resources.

"Throughout her career, Beverly has demonstrated a deep commitment to Graybar's long-term success and our culture of employee ownership," said Graybar's Chairman, President and CEO Kathleen M. Mazzarella. "We thank Beverly for her many contributions to our business, and we wish her all the best in retirement."

Graybar, a Fortune 500 corporation and one of the largest employee-owned companies in North America, is a leader in the distribution of high quality electrical, industrial, automation and connectivity products, and specializes in related supply chain management and logistics services. Through its network of 355 North American distribution facilities, it stocks and sells products from thousands of manufacturers, helping its customers power, network, automate and secure their facilities with speed, intelligence and efficiency. For more information, visit www.graybar.com or call 1-800-GRAYBAR.

Media Contact:

Tim Sommer

(314) 578-7672

[email protected]

SOURCE Graybar

Share this article

CHICAGO, Sept. 10, 2026 /PRNewswire/ -- Cboe Global Markets, Inc. (Cboe: CBOE), a leading global markets operator and pioneer in equity and index derivatives, today announced that Craig Donohue, Chief Executive Officer, Prashant Bhatia, Executive Vice President and Head of Enterprise Strategy & Corporate Development, Jill Griebenow, Executive Vice President and Chief Financial Officer, and Rob Hocking, Executive Vice President and Global Head of Derivatives, will present at the Barclays Global Financial Services Conference in New York City on Wednesday, September 16, at 12:00 p.m. ET.

The live webcast and replay of the presentation will be accessible at ir.cboe.com, under Events and Presentations. The archived webcast is expected to be available within an hour of the presentation.

About Cboe Global Markets

Cboe Global Markets (Cboe: CBOE) is a leading global markets operator with a long history of innovation in equity and index derivatives. Since launching the world's first listed options exchange in 1973, Cboe has pioneered landmark products, including the introduction of S&P 500® index options and the creation of the VIX® Index, the world's leading gauge of market volatility, reshaping how investors manage risk and access opportunity. Today, Cboe operates derivatives, equities, and FX markets, providing trading, clearing, and investment solutions for customers worldwide. To learn more, visit www.cboe.com.

CBOE-C

CBOE-OE

Cboe®, Cboe Global Markets®, and VIX ® are registered trademarks or service marks of Cboe Exchange, Inc and S&P 500® is a registered trademark of Standard & Poor's Financial Services LLC. All other trademarks and service marks are the property of their respective owners.

SOURCE Cboe Global Markets, Inc.

Share this article

Largest USA Kidney Group Hails Pine Bluff Hometown Hero

Little Rock Hosts Kidney Patient Meeting on Science, AI, New Treatments

WASHINGTON, Sept. 10, 2026 /PRNewswire/ -- The American Association of Kidney Patients (AAKP), the nation's oldest and largest independent and nonpartisan kidney patient advocacy organization, began its 51st annual National Patient Meeting September 10 – 13, 2026, in Little Rock, Arkansas, with the induction of a well-known Arkansas kidney disease educator and advocate to its Kidney Advocate Hall of Fame – Bob Abbott of Pine Bluff.

Abbott, owner and manager of Abbott Enterprises Inc. in Pine Bluff, was inducted into the AAKP Kidney Advocate Hall of Fame as part of the inaugural class of nationally respected influencers in kidney research and innovation. Abbott was honored for five decades of kidney advocacy alongside medical experts, federal officials, patient advocates, and researchers. The ceremony took place at the William J. Clinton Presidential Center during AAKP's Policy Forum session. The AAKP National Patient Meeting, an in-person and online event, includes over 30 top kidney disease and treatment innovation experts. Admission and meals are free to kidney patients, family members, care partners, and living organ donors. Pre-registration is easy throughout the event for in-person walk-in attendees or online at https://bit.ly/AAKPNPM.

AAKP's Hall of Fame tribute to Abbott includes the language: "In recognition of more than five decades of extraordinary, selfless service on behalf of kidney patients and their families, unwavering commitment to improving care access and opportunity for all patients, and to make certain elected leaders respect the voices of patients. A Lifetime of Impact – A Legacy of Effective Advocacy." His extraordinary volunteer service has earned national recognition, including a President's Volunteer Service Award in 2020, following his nomination by AAKP, and the President's Lifetime Achievement Award in 2022, after AAKP again recommended him for the honor. The Lifetime Achievement Award represents the highest level of presidential recognition for volunteer service.

Abbott's advocacy began when his father, Floyd Abbott, developed kidney failure at a time when access to life-sustaining dialysis was severely limited and financially out of reach for many families. The Abbott family purchased a dialysis machine to keep his father alive—an experience that motivated Bob to fight so that other families would not face the same barriers to care. In Arkansas, Bob proposed legislation that led to the creation of the Arkansas Kidney Disease Commission in 1971, one of the nation's earliest state efforts to assist people with kidney failure, and he served as one of its original members. He also became a founding member of the National Kidney Foundation of Arkansas. At the federal level, Bob and his family helped bring the realities of kidney failure and the promise of dialysis to the attention of influential policymakers, including House Ways and Means Committee Chairman Wilbur Mills, as momentum grew for the landmark 1972 legislation extending Medicare coverage to people with kidney failure.

AAKP President Edward V. Hickey, III, a chronic kidney disease patient, stated, "Bob's story is a powerful reminder of the impact a family caregiver can have far beyond their own family. What began as a fight to save his father's life became a lifetime commitment to ensuring that kidney patients across America have access to lifesaving care, a voice in the decisions that affect them, and the opportunity to live longer and better lives. And it is especially meaningful to honor Bob, a fine American and true patriot, here in his home state of Arkansas." Hickey is a U.S. Marine Corps Veteran, a former senior Congressional aide, and has served in appointed roles in two presidential administrations. He currently serves on the American Board of Internal Medicine's (ABIM) Nephrology Specialty Board and as the Chair of the AAKP Veterans Health Initiative.

AAKP Vice President and Chair of Policy Paul T. Conway, a 49-year kidney patient and 29-year transplant recipient, stated, "Bob Abbott's service reflects his empathy for his fellow human beings, the depth of his character and his faith. AAKP held our first Policy Forum at the William J. Clinton Presidential Center in 2011 at Bob's suggestion, marking the first time a national kidney group spotlighted the linkage between status quo kidney dialysis care and patient unemployment. Bob has been a fearless champion for principled public policy and medical innovation as a means for ending dependency, economic insecurity, and preventable death." Conway is a former Chief of Staff of the U.S. Department of Labor and served as the inaugural Chair of the U.S. Food and Drug Administration's Patient Engagement Advisory Committee (PEAC). He was honored by former Arkansas Governor Asa Hutchinson as an Arkansas Traveler for his work to improve kidney care and the well-being of Arkansas residents.

AAKP provides advocacy skills and social media training for patients and organ donors through its Center for Patient Engagement and Advocacy and National Patient Meeting with a faculty of allied government affairs and political experts. AAKP advocates help advance kidney community efforts, coordinated by the American Society of Nephrology (ASN) (view report), to expand Congressional appropriations and taxpayer investments in kidney science and research by up to $1.8 billion, through the National Institutes of Health and the U.S. Department of Defense. AAKP is committed to American leadership in the discovery of safe, next-generation kidney technologies while counteracting the pacing threat of communist China and its state-orchestrated efforts to dominate biotech, manipulate the drug supply chain, and limit patient choice.

Follow AAKP on social media at @kidneypatient on Facebook, @kidneypatients on X, and @kidneypatients on Instagram, and visit http://www.aakp.org for more information. AAKP patient advocates advance bipartisan kidney policy including: passage of the bipartisan law modernizing the Organ Procurement and Transplantation Network (OPTN) (2023); lifetime transplant drug coverage for kidney patients (2020); the historic Executive Order on Advancing American Kidney Health signed by President Donald Trump (2019); job protections for living organ donors under the Family Medical Leave Act (FMLA) via the U.S. Department of Labor (2018); and Congressional approval of HIV positive organ transplants for HIV positive patients (2013).

MEDIA CONTACT:

Brendan LaCivita

National and Medical Media Specialist

[email protected]

(813) 906-7740

SOURCE American Association of Kidney Patients

Share this article

SAN FRANCISCO, Sept. 10, 2026 /PRNewswire/ -- Carlsquare has advised DryvIQ, a leader in intelligent unstructured data management, on its acquisition by Nasuni, the unstructured data platform for enterprise teams and AI. The acquisition adds AI-powered content intelligence and governance capabilities to the Nasuni File Data Platform — including content-level discovery and classification, sensitivity detection, and automated policy-driven governance — giving organizations greater visibility and control over unstructured data, not just within Nasuni, but across more than 40 cloud and on-premises repositories.

"Our customers are looking to us for help with data strategies to support safe AI access in a world of rising infrastructure costs. To meet that need, this year we've added best-in-class edge performance with Resilio, permission-aware AI access with AI Activate, and now content intelligence and governance with DryvIQ," said Nick Burling, Chief Product Officer at Nasuni. "With UniFS as the foundation, no other solution manages, moves, classifies, governs, and activates enterprise file data in a single platform. Customers have been attempting to stitch together a solution across multiple vendors for years. Now Nasuni provides one platform to manage, protect, and activate unstructured data with proven impact on both cost reduction and productivity gains."

"Organizations are increasingly focused on turning unstructured data into a strategic asset, but content is scattered across dozens of repositories, and most of it has never been classified," said Mark Brazeau, Founder and Chief Strategy Officer at DryvIQ. "By joining Nasuni, we can bring our content intelligence and governance capabilities directly into a cloud-native file platform, giving customers a single, governed foundation to classify, protect, and activate data wherever it lives."

Matt Doyle, President at DryvIQ, added: "Joining Nasuni puts DryvIQ's AI-powered content intelligence and governance inside the platform where enterprise data already lives, giving customers a single, governed foundation to classify, manage, protect, and activate that data. Susan Blanco and her team at Carlsquare have extensive knowledge of the relevant data software landscape, and that made a real difference in the outcome for our shareholders

Financial terms of the transaction were not disclosed.

SOURCE Carlsquare, LLC

Share this article

Nationally recognized transportation leader to guide strategy and help clients advance passenger rail, transit and multimodal transportation programs

ARLINGTON, Va., Sept. 10, 2026 /PRNewswire/ -- Henrika Buchanan has been named HNTB's transit and rail market sector leader. With more than 27 years of transportation leadership experience, Buchanan will guide the firm's strategy, growth and service for transit and rail clients, collaborating with division, office and practice leaders across the firm to align capabilities, support client priorities and advance HNTB's commitment to delivering integrated solutions across the full spectrum of transit and rail infrastructure.

"Henrika's ability to connect industry, policy and business perspectives, combined with her understanding of the opportunities and priorities shaping transit and rail agencies, has made her one of the most respected voices in the industry," said Mike Inabinet, PE, president of markets and services at HNTB. "Throughout her career she has brought together industry leaders and fostered collaborative partnerships that have helped advance some of the transportation industry's most significant projects and programs. Her experience, perspective and collaborative approach make her exceptionally well positioned to lead our transit and rail market sector into the future."

Prior to joining HNTB in 2021, Buchanan served in several senior leadership positions within the Federal Transit Administration (FTA), including associate administrator for transit safety and oversight and chief safety officer. During her federal service, she helped lead national transit safety, capital investment and program oversight initiatives while overseeing major federal funding and recovery programs.

Since joining HNTB, Buchanan has played a key role in building on the firm's longstanding leadership in the transit and rail industry, providing strategic counsel to clients and supporting a variety of complex transportation programs.

"As transit agencies, passenger rail operators and transportation leaders navigate changing funding environments, evolving customer expectations and growing infrastructure needs, the opportunity to help shape the future of mobility has never been greater," Buchanan said. "HNTB's depth of industry experience and technical expertise is unmatched, and I look forward to working alongside our team and clients to shape the next generation of transportation systems that connect people, expand opportunity and support long-term economic growth."

Buchanan was recognized in 2023 as one of the Conference of Minority Transportation Officials Women Who Move the Nation, which highlights female leaders in transportation for their excellence, innovation and dedication to the transportation industry.

About HNTB

For more than a century, HNTB Corporation has been at the forefront of designing and advancing transportation infrastructure that enhances mobility and improves local communities. With client relationships spanning decades, we understand infrastructure life cycles and have perspective and experience to solve the most complex technical, financial and operational challenges with vision and imagination. As employee owners committed to excellence, we prioritize client success while delivering a full spectrum of infrastructure-related services. Discover HNTB's Spark at www.hntb.com, or follow us on LinkedIn, X, Facebook or Instagram.

SOURCE HNTB Corporation

Share this article

WASHINGTON, D.C., Sept. 10, 2026 /PRNewswire/ -- The U.S. Consumer Product Safety Commission (CPSC) today announced that the Honorable Paul Brubaker has joined the agency as its new Executive Director. In this role, Brubaker serves as CPSC's chief operating officer, overseeing the agency's programmatic, operational, and administrative functions. He will also manage the agency's regulatory portfolio and help lead CPSC's efforts to identify and address hazards to consumers.

Brubaker brings nearly four decades of leadership experience across the public and private sectors, with particular expertise in technology, cybersecurity, data analytics, organizational strategy, and federal management. In 2007 he was confirmed by the United States Senate to head the Research and Innovative Technology Administration at the U.S. Department of Transportation. Brubaker also held senior leadership positions at the Departments of Veterans Affairs, Energy, and War, where his work has focused on modernizing government operations, strengthening information systems, and using technology and data to improve mission performance.

Most recently, Brubaker served as Chief Mission Officer at Commence, a private sector firm focusing on the integration of data, AI, and clinical healthcare expertise, where he advised federal health agencies on strategies to improve mission performance and health outcomes. Throughout his career, he has worked at the intersection of government, technology, and management, helping organizations address complex operational and technical challenges.

"Paul is an extraordinarily accomplished executive who brings precisely the combination of government, technology, and private-sector experience that CPSC needs at this moment," said Acting Chairman Peter A. Feldman. "He understands the challenges facing agencies like ours and, more importantly, knows how to solve them."

"Technology modernization, data analytics, and information security are no longer simply support functions—they are mission-critical capabilities. Our ability to protect American families increasingly depends on how effectively we use technology and data to identify emerging hazards, target dangerous products, and deploy our resources where they can have the greatest impact. I am grateful that Paul has once again chosen public service, and especially pleased that he has chosen to serve at CPSC."

Brubaker received a Master of Public Administration from Kent State University and a Bachelor of Arts in Political Science and History from Youngstown State University.

About CPSC

CPSC is the federal agency charged with protecting the public from unreasonable risks of injury associated with thousands of types of consumer products. Deaths, injuries, and property damage from consumer product-related incidents cost the nation more than $1 trillion annually. Since the agency was established more than 50 years ago, CPSC has worked to ensure the safety of consumer products, contributing to a decline in related injuries.

Federal law prohibits any person from selling products subject to a Commission-ordered recall or to a voluntary recall undertaken in consultation with CPSC.

For lifesaving information:

- Visit CPSC.gov.

- Sign up to receive our e-mail alerts.

- Follow us on Facebook, Instagram, X, BlueSky, Threads, LinkedIn and Truth Social.

- Report a dangerous product or a product-related injury on www.SaferProducts.gov.

- Call CPSC's Hotline at 800-638-2772 (TTY 800-638-8270).

- Contact a media specialist.

Release Number: 26- 767

SOURCE U.S. Consumer Product Safety Commission

Share this article